HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway

被引:0
|
作者
Zhou, Siqi [1 ,2 ]
Wang, Zhangding [2 ]
Zhao, Dian [3 ]
Fu, Yao [4 ]
Zhang, Shu [1 ,2 ]
Wang, Zhiping [5 ]
Zou, Xiaoping [1 ,2 ]
机构
[1] Jiangsu Univ, Dept Gastroenterol, Nanjing Drum Tower Hosp, Clin Coll, 321 Zhongshan Rd, Nanjing 210008, Peoples R China
[2] Nanjing Univ, Dept Gastroenterol, Affiliated Hosp, Nanjing Drum Tower Hosp,Med Sch, Nanjing 210008, Peoples R China
[3] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Natl Clin Res Ctr Digest Dis, State Key Lab Holist Integrat Management Gastroint, Xian 710032, Peoples R China
[4] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Pathol, Affiliated Hosp,Med Sch, Nanjing 210008, Peoples R China
[5] Xuzhou Med Univ, Dept Anesthesiol, Affiliated Hosp, 99 Huaihai West Rd, Xuzhou 221000, Peoples R China
基金
中国国家自然科学基金;
关键词
Pancreatic cancer; HHLA2; Tumor-associated macrophages; Migration; Invasion; B7; FAMILY; IDENTIFICATION; MEMBER;
D O I
10.1186/s12957-024-03409-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Human endogenous retrovirus subfamily H long terminal repeat associating protein 2, (HHLA2), a member of B7 family, exhibits heightened expression in various malignant tumors. However, the exact functions of HHLA2 in pancreatic cancer (PC) remain incompletely elucidated.Methods We initially conducted an analysis of the B7 family members' expression pattern in pancreatic tumor samples and adjacent normal tissues using The Cancer Genome Atlas (TCGA) database. Subsequently, immunohistochemistry, RT-qPCR and western blot methods were used to assess HHLA2 expression levels in PC tissues and cell lines. Furthermore, after silencing HHLA2 in PC cell lines, cell migration and proliferation of PC cells were detected by wound healing and CCK-8 assays, and cell invasion of PC cells was detected by transwell assays. We also investigated the regulation of epithelial-mesenchymal transition (EMT) markers and levels of EGFR, MEK, ERK1/2, mTOR and AKT via western blot analysis. Finally, the correlation between HHLA2 expression and immune infiltration was further explored.Results Silencing of HHLA2 resulted in the inhibition of PC cell proliferation, migration and invasion, potentially through the suppression of the EGFR/MAPK/ERK and mTOR/AKT signaling pathway. Additionally, silencing HHLA2 led to the inhibition of M2-type polarization of tumor associated macrophages (TAMs).Conclusion The knockdown of HHLA2 was observed to inhibit the migration and invasion of PC cells through the regulation of the EMT process and EGFR/MAPK/ERK and mTOR/AKT pathway. Furthermore, silencing HHLA2 was found to modulate M2 polarization of TAMs. These finding suggest that HHLA2 could be a promising therapeutic target for Pancreatic cancer.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Upregulation of MELK promotes chemoresistance and induces macrophage M2 polarization via CSF-1/JAK2/STAT3 pathway in gastric cancer
    Su, Pengfei
    Yu, Tian
    Zhang, Yingjing
    Huang, Hongyun
    Chen, Moxi
    Cao, Can
    Kang, Weiming
    Liu, Yuqin
    Yu, Jianchun
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [32] Macrophage peroxiredoxin 5 deficiency promotes lung cancer progression via ROS-dependent M2-like polarization
    Seong, Jung Bae
    Kim, Bokyung
    Kim, Soyoon
    Kim, Mi Hye
    Park, Young-Ho
    Lee, Youngjeon
    Lee, Hong Jun
    Hong, Chang-Won
    Lee, Dong-Seok
    FREE RADICAL BIOLOGY AND MEDICINE, 2021, 176 : 322 - 334
  • [33] circRNA TCFL5 Promote Esophageal Cancer Progression by Modulating M2 Macrophage Polarization via the miR-543-FMNL2 Axis
    Lin, Chengbin
    Xi, Yong
    Yu, Hongyan
    Wang, Zheng
    Chen, Xiaohan
    Shen, Weiyu
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [34] Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways
    Hu, Yuan
    Jing, Jiayu
    Shi, Yu
    Zhang, Pengchuang
    Dong, Danfeng
    Wu, Yinying
    Dong, Xuyuan
    Li, Enxiao
    Fan, Yangwei
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (07) : 3306 - 3316
  • [35] RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-κB pathway in oral squamous cell carcinoma
    Dan, Hongxia
    Liu, Sai
    Liu, Jiajia
    Liu, Dongjuan
    Yin, Fengying
    Wei, Zihao
    Wang, Jiongke
    Zhou, Yu
    Jiang, Lu
    Ji, Ning
    Zeng, Xin
    Li, Jing
    Chen, Qianming
    MOLECULAR ONCOLOGY, 2020, 14 (04) : 795 - 807
  • [36] Human leukocyte antigen DR alpha inhibits renal cell carcinoma progression by promoting the polarization of M2 macrophages to M1 via the NF-κB pathway
    Xiong, Feng
    Wang, Bowen
    Zhang, Haoxun
    Zhang, Guoling
    Liu, Yiwen
    Liu, Yujie
    Wang, Chunyang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 144
  • [37] The role of NFATc1/c-myc/PKM2/IL-10 axis in activating cervical cancer tumor-associated M2 macrophage polarization to promote cervical cancer progression
    Tan, Jiahong
    Yang, Linna
    Zhao, Han
    Ai, Ying
    Ren, Li
    Zhang, Fen
    Dong, Wei
    Shi, Ru
    Sun, Dawei
    Feng, Yun
    EXPERIMENTAL CELL RESEARCH, 2022, 413 (02)
  • [38] Ginsenoside Re inhibits non-small cell lung cancer progression by suppressing macrophage M2 polarization induced by AMPKα1/STING positive feedback loop
    Tang, Xiaoyu
    Zhu, Man
    Zhu, Zeren
    Tang, Wenjun
    Zhang, Hongmei
    Chen, Yanbin
    Liu, Feng
    Zhang, Yanmin
    PHYTOTHERAPY RESEARCH, 2024, 38 (11) : 5088 - 5106
  • [39] UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation
    Cao, Jing-Zhu
    Nie, Gang
    Hu, Hao
    Zhang, Xiao
    Ni, Chen-Ming
    Huang, Zhi-Ping
    Qiao, Guang-Lei
    Ouyang, Liu
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1444 - 1453
  • [40] The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK/STAT and inhibits pancreatic cancer invasion and metastasis
    Hu, Wei-Min
    Liu, Si-Qing
    Zhu, Kong-Fan
    Li, Wei
    Yang, Zhi-Jian
    Yang, Qiang
    Zhu, Zhong-Chao
    Chang, Jian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 121